Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...

The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase ...

Detailed price information for Jade Biosciences Inc (JBIO-Q) from The Globe and Mail including charting and trades.

Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...

Agios Pharmaceuticals said on Tuesday it is discontinuing development of its sickle cell disease treatment ​after trial ...

Stock drops after development setbackAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company announced it will discontinue development of tebapivat for sickle cell ...

Hepcidin and ferritin-based indices help identify patients with active inflammatory bowel disease who are less likely to respond to iron therapy.

Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.

Updated American Cancer Society guidance is reshaping colorectal cancer screening, expanding testing options and raising ...

The continent should take the matter of resistance very, very seriously...Resistance should be seen as an emergency situation.” ...

First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from ...